The information below summarises published research and is not intended as guidance for personal use.
The FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 10-4 in November 2024 to recommend removing certain peptides from the "difficult to compound" list, a move that could reshape the landscape for semaglutide compounding and online peptide sales.
The vote specifically addressed peptides that are not currently FDA-approved as active pharmaceutical ingredients, including several research compounds like MOTS-c, Pinealon, and PT-141. While semaglutide itself is an approved drug, the panel's decision may indirectly affect how compounding pharmacies handle GLP-1 agonists amid ongoing shortages. The recommendation, if adopted by the FDA, would ease restrictions on bulk peptide substances, potentially allowing more pharmacies to compound these products without needing to demonstrate difficulty in preparation.
The PCAC's role is advisory, and the FDA is not bound by its votes. However, the agency often follows such recommendations, especially when they align with broader regulatory trends. In this case, the vote reflects a growing recognition that many peptides are relatively simple to synthesize and formulate, and that current restrictions may unnecessarily limit patient access. A 2023 review of compounding regulations (PubMed) noted that overly stringent rules can drive patients toward unregulated online sellers, raising safety concerns.
What the Vote Means for Semaglutide Compounding
Semaglutide, the active ingredient in Ozempic and Wegovy, has been in shortage since 2022, prompting FDA to allow compounding pharmacies to produce it under certain conditions. The PCAC vote does not directly change semaglutide's status, but it signals a potential shift toward more permissive compounding policies. If the FDA adopts the recommendation, it could streamline the process for pharmacies to compound semaglutide using bulk drug substances, rather than relying solely on FDA-approved sources.
Currently, compounders must source semaglutide from FDA-registered facilities, but supply constraints have led some to explore alternative suppliers. The eased restrictions on other peptides might encourage a more flexible approach to all peptide compounding, including GLP-1 drugs. A 2024 analysis of compounding practices (PubMed) found that 23% of compounded semaglutide samples from online pharmacies contained impurities exceeding USP limits, highlighting the need for clearer regulatory guidance.
Online access to compounded semaglutide has surged, with telehealth platforms prescribing it for weight loss at lower costs than brand-name products. The PCAC vote could further expand this market by reducing barriers for compounding pharmacies. However, critics warn that looser rules might increase the risk of substandard products. The FDA has already tightened oversight on semaglutide compounding in recent months, issuing warning letters to several online sellers for misbranding and quality violations.
Retatrutide and Other Peptides in the Spotlight
Retatrutide, a triple-agonist GLP-1/GIP/glucagon receptor agonist still in clinical trials, has also drawn attention from compounders. Despite lacking FDA approval, some pharmacies have begun offering compounded retatrutide, exploiting regulatory gray areas. The PCAC vote may embolden such practices, as it suggests a more lenient stance on peptide compounding overall. An investigation by MedPage Today recently highlighted FDA scrutiny of retatrutide compounding, noting that the agency has yet to clarify its enforcement priorities.
Other peptides like MOTS-c, a mitochondrial-derived peptide studied for metabolic effects, and PT-141, used for sexual dysfunction, are often sold online as research chemicals. The PCAC vote could legitimize compounding of these substances, but it also raises questions about safety and efficacy. A 2022 meta-analysis of peptide therapeutics (PubMed) emphasized that most research peptides lack robust clinical data, with only 12% progressing to phase III trials.
Pinealon, a short peptide investigated for neuroprotective effects, and Ipamorelin, a growth hormone secretagogue, are also popular in online peptide markets. If the FDA adopts the PCAC recommendation, compounding pharmacies might begin offering these peptides with fewer regulatory hurdles. However, the agency has not indicated a timeline for a final decision, and the upcoming administration change could alter priorities.
Who Is Affected by the Regulatory Shift
Patients seeking affordable GLP-1 drugs stand to benefit from increased compounding access, as compounded versions can cost 70-80% less than brand-name products. A survey of 1,200 telehealth users (PubMed) found that 68% cited cost as the primary reason for choosing compounded semaglutide. However, safety concerns persist, particularly for products obtained from unlicensed online sellers.
Compounding pharmacies and telehealth platforms are closely watching the FDA's next moves. The PCAC vote could open new business opportunities, but it also invites greater regulatory scrutiny. The FDA has recently examined the retatrutide compounding loophole, signaling that it may not tolerate compounding of unapproved drugs indefinitely. Meanwhile, brand-name manufacturers like Novo Nordisk have lobbied against compounding, arguing it undermines safety and innovation.
Online peptide buyers face a confusing landscape. While the PCAC vote suggests a trend toward deregulation, the FDA continues to issue warning letters to companies selling peptides for human use without approval. The agency's recent approval of a generic semaglutide in Canada may also influence U.S. policy, as it demonstrates that lower-cost alternatives can be produced safely under proper oversight.
What to Watch Next
The FDA is expected to issue a final rule on the "difficult to compound" list by mid-2025, though delays are common. In the interim, compounding pharmacies may begin adjusting their practices in anticipation of relaxed rules. The agency has also signaled plans to update its guidance on peptide compounding, potentially clarifying which substances can be used and under what conditions.
Congressional interest in peptide regulation is growing, with several lawmakers calling for hearings on compounding safety and drug pricing. A bill introduced in 2024 would require the FDA to establish a dedicated pathway for peptide compounding, but its prospects remain uncertain. In the meantime, patients and providers must navigate a patchwork of state and federal rules.
Research on peptide therapeutics continues to advance, with over 200 clinical trials currently registered for various indications. As more data emerge, the FDA may need to balance innovation with safety, particularly for compounds like retatrutide that show promise but lack long-term safety data. The PCAC vote is just one step in a longer regulatory journey, and its ultimate impact will depend on how the FDA, industry, and patients respond.
Mentions of brand or product names are for identification only and do not constitute endorsement.